Can cholesterol drug or milk thistle tame sepsis?
NCT ID NCT07572552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs—fenofibrate (a cholesterol medicine) and silymarin (from milk thistle)—in 66 adults with sepsis. The goal is to see if either can reduce harmful inflammation and organ damage better than standard care alone. The trial is not yet recruiting and is in Phase 2, meaning it's still early and small.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fenofibrate and silymarin
- What this could lead to
- If it works, this could point toward a new way to control inflammation and organ damage in sepsis patients.
- What could go wrong
- This is a small, early-phase trial with only 66 participants. The results may not apply to all sepsis patients, and neither drug may prove better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can tailored nutrition boost recovery in the ICU?
- Blood markers may foretell brain fog after sepsis
- A hidden clue in the fingertips: could a pulse oximeter reading forecast sepsis outcomes?